Houston、TXにおける軟部組織肉腫の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、軟部組織肉腫に関する33件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
被験者募集中第1/2相
- UT MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Baylor College of Medicine, Houston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
被験者募集中第1/2相
- University Of Texas MD Anderson Cancer Center, Houston
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
被験者募集中第1相
- UT MD Anderson Cancer Center, Houston
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
被験者募集中第1相
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- UT MD Anderson Cancer Center, Houston
Actinium Therapy for Late-stage Aggressive Sarcomas
被験者募集中第1相
- MD Anderson Cancer Center, Houston
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
被験者募集中第2相
- MD Anderson Cancer Center, Houston
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
被験者募集中
- M D Anderson Cancer Center, Houston
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
被験者募集中第1相
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
被験者募集中観察研究
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
被験者募集中第2相
- M D Anderson Cancer Center, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
被験者募集中第2相
- The University of Texas M. D. Anderson Cancer Center, Houston
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
被験者募集中第2相
- M.D. Anderson Children's Cancer Hospital, Houston
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
被験者募集中
- M D Anderson Cancer Center, Houston
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
被験者募集中第1相
- Texas Children's Hospital, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
被験者募集中観察研究
- Oncology Consultants, Houston
他の都市における軟部組織肉腫の試験
- New York City, NY20件の研究
- Boston, MA18件の研究
- St. Louis, MO14件の研究
- Los Angeles, CA13件の研究
- Columbus, OH13件の研究
- Washington, DC12件の研究
- Memphis, TN11件の研究
- Philadelphia, PA10件の研究
- Rochester, MN9件の研究
- Nashville, TN9件の研究
- Queens, NY9件の研究
- Aurora, CO9件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん90件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん62件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。